Good morning, everyone, and how are you today? We are doing just fine, thank you, despite a decidedly cold wind blowing about the Pharmalot grounds. Our short person has successfully departed for another day of learning at the local schoolhouse and our official mascot is comfortably snoozing in a corner. This leaves us to focus on the task at hand, which is to forage for interesting items and the like. So time to get cracking. Here are a few tidbits to help on your own quest. Hope all goes well today.
Small biotech companies — most of whom stick to science, not politics — are speaking up about the House Democrats’ drug pricing bill because they are uniquely worried that the policies included in the legislation bill will dry up venture capital funding that drives their industry, STAT writes. In turn, this would make it impossible for other small startups that turn basic research into new medicines to get off the ground. “This bill could have devastating effects on our industry, period. End of discussion,” says Paul Hastings of Nkarta Therapeutics.